Trastuzumab
Based on 66 publication(s) in Google Scholar
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
For research use only. We do not sell to patients.
- Purity: 99.80%
- CAS No.: 180288-69-1
- Molecular Weight:145.36 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Trastuzumab
More- Signal Transduct Target Ther. 2020 Sep 14;5(1):200. [Abstract]
- Chem. 2025 Aug 19.
- Nat Commun. 2026 May 14. [Abstract]
- Nat Commun. 2026 Apr 23;17(1):5600. [Abstract]
- Nat Commun. 2026 Mar 2. [Abstract]
- Nat Commun. 2025 Jul 4;16(1):6152. [Abstract]
- Nat Commun. 2023 Sep 14;14(1):5699. [Abstract]
- Nat Commun. 2020 Feb 26;11(1):1049. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(20):e19574. [Abstract]
- Chem Eng J. 2023 Oct 15, 474, 145951.
- Biomaterials. 2024 Sep 2:313:122798. [Abstract]
- J Exp Clin Cancer Res. 2019 May 22;38(1):214. [Abstract]
- Med. 2023 Jul 14;4(7):457-477.e8. [Abstract]
- J Control Release. 2025 Apr 15:113738. [Abstract]
- Biosens Bioelectron. 2026 Mar 1:295:118311. [Abstract]
- Cancer Lett. 2020 Apr 10;475:53-64. [Abstract]
- Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
- Cell Commun Signal. 2025 Jul 10;23(1):333. [Abstract]
- Cell Commun Signal. 2025 Feb 22;23(1):106. [Abstract]
- EMBO Mol Med. 2025 Feb;17(2):336-364. [Abstract]
- Biomed Pharmacother. 2025 Jun 16:189:118245. [Abstract]
- Biomed Pharmacother. 2022 Jun:150:113051. [Abstract]
- Elife. 2019 Jun 7:8:e46983. [Abstract]
- Anal Chim Acta. 2021 Apr 15:1154:338306. [Abstract]
- Mol Cancer Ther. 2024 Nov 4;23(11):1639-1651. [Abstract]
- Commun Biol. 2024 Dec 31;7(1):1719. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115160. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101416. [Abstract]
- Mol Pharm. 2025 Jul 7;22(7):3793-3802. [Abstract]
- Nanomaterials. 2021 Nov 24;11(12):3181. [Abstract]
- Transl Oncol. 2024 Jun:44:101928. [Abstract]
- Bioconjug Chem. 2026 May 20;37(5):942-949. [Abstract]
- Bioconjug Chem. 2025 Aug 21. [Abstract]
- Biomedicines. 2023 Jul 25;11(8):2090. [Abstract]
- EJNMMI Radiopharm Chem. 2025 Apr 4;10(1):16. [Abstract]
- Diagnostics (Basel). 2022 Feb 25;12(3):591. [Abstract]
- Mol Carcinog. 2026 May 7. [Abstract]
- Breast Cancer Res Treat. 2021 Jun;187(3):613-624. [Abstract]
- Antibodies. 2025 Apr 11;14(2):36. [Abstract]
- PLoS One. 2026 Apr 3;21(4):e0346567. [Abstract]
- Electrophoresis. 2026 Mar 24. [Abstract]
- Biochem Biophys Res Commun. 2024 Aug 19:739:150568. [Abstract]
- Biochem Bioph Res Co. 2020 Dec 10;533(3):533-539. [Abstract]
- Drug Chem Toxicol. 2026 Jan 29:1-10. [Abstract]
- bioRxiv. 2026 Jun 19.
- SSRN. 2026 Jun 8.
- chemRxiv. 2026 May 3.
- bioRxiv. 2026 May 27.
- bioRxiv. 2026 Apr 23.
- chemRxiv.
- SSRN. 2025 Oct 13.
- bioRxiv. 2025 Jun 16:2025.06.11.658997. [Abstract]
- Patent. US20250127918A1.
- University of Michigan
- Patent. US20250152713A1.
- SSRN. 2025 Apr 11.
- bioRxiv. 2025 Apr 26:2025.04.22.649788. [Abstract]
- Patent. US20240293556A1.
- bioRxiv. 2024 Nov 10:2024.08.12.607630. [Abstract]
- Nano Trends. 2024 Sep.
- Patent. US20230340070A1.
- bioRxiv. 2023 Oct 5.
- University of Washington. 2021 Nov.
- Patent. US20190151462A1
- Biochemistry, Molecular Bio, and Biophysics. University of Minnesota. 2019 Feb.
Customer Validation & Images
-
ELISA
-
WB
-
Cell Proliferation/Viability Assay
-
Gel Electrophoresis
-
Cell Proliferation/Viability Assay
All Radionuclide-Drug Conjugates (RDCs) Isoforms
MoreAll EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
RDC Antibody |
HER2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MOLT-4 | IC50 |
3.25 μM
Compound: 1a
|
Cytotoxic effect on the growth of human T-and B-lymphoblastoid cell lines(MOLT-4 and MGL-8) evaluated by measuring inhibition of thymidine intake in presence of 10 uM deoxyguanosine
Cytotoxic effect on the growth of human T-and B-lymphoblastoid cell lines(MOLT-4 and MGL-8) evaluated by measuring inhibition of thymidine intake in presence of 10 uM deoxyguanosine
|
[PMID: 1573639] |
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Trastuzumab on AHC2 biosensor, can bind Her2/CD340 Protein, Human (Biotinylated, HEK293, His, HY-P78882) with an affinity constant of 6.903E-10 M as determined in BLI assay. -
Trastuzumab has a significant ADCC effect on BT474 cells in a dose-dependent manner.The EC50 for this effect is 26.36 and 32.09 ng/mL. -
Trastuzumab has a significant ADCC effect on SK-BR-3 cells in a dose-dependent manner.The EC50 for this effect is 14.43 and 16.70 ng/mL. -
Immobilized HER2/CD340 Protein, Human (630a.a, HEK293, His, HY-P70254) can bind Trastuzumab.The EC50 for this effect is 2.16 ng/mL.
Chemical Information
-
CAS No. 180288-69-1
-
Appearance Solid
-
Molecular Weight 145.36 kDa
-
Color White to light yellow
-
SMILES
[Trastuzumab]
-
Synonyms
Anti-Human HER2, Humanized Antibody
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (66)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. [Abstract]2020 Sep 14;5(1):200. PMID: 32929063 -
-
Nat Commun
α-Halothioamide warheads with enhanced cysteine reactivity and specificity for covalent protein labelling. [Abstract]2026 May 14. PMID: 42151150 -
Nat Commun
High-throughput single-vesicle imaging platform for direct extracellular vesicle profiling of human plasma. [Abstract]2026 Apr 23;17(1):5600. PMID: 42020418 -
Nat Commun
Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering. [Abstract]2026 Mar 2. PMID: 41771920 -
Nat Commun
Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in bacteria. [Abstract]2025 Jul 4;16(1):6152. PMID: 40610439
Trastuzumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 4;16(1):6152. [Abstract]
ELISA analysis of same constructs with FcγRIIIA-V158 as immobilized antigen.
-
Nat Commun
Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer. [Abstract]2023 Sep 14;14(1):5699. PMID: 37709778
Trastuzumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 14;14(1):5699. [Abstract]
Trastuzumab (TZB) (3.16-1000 nM; 14 h) is cytotoxic to GBC-SD and EH-GB1 cells.
-
Nat Commun
2020 Feb 26;11(1):1049. PMID: 32103000
Trastuzumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Feb 26;11(1):1049. [Abstract]
Trypsin microdroplet digestion of the therapeutic antibody Trastuzumab with ESSI-MS (−3 kV) after PAGE gel separation.
-
Adv Sci (Weinh)
PD-L1-Binding Antigen Presenters: Redirecting Vaccine-Induced Antibodies for Cancer Immunotherapy. [Abstract]2026 Apr;13(20):e19574. PMID: 41668552 -
-
Biomaterials
2024 Sep 2:313:122798. PMID: 39244823 -
J Exp Clin Cancer Res
GPAA1 promotes gastric cancer progression via upregulation of GPI-anchored protein and enhancement of ERBB signalling pathway. [Abstract]2019 May 22;38(1):214. PMID: 31118109
Trastuzumab purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 22;38(1):214. [Abstract]
Tumours obtained from mice injected subcutaneously with HGC-27 cells with either over- or normal expression of GPAA1 and treated with vehicle or Trastuzumab (25 mg/kg, twice daily, 35 days).
Trastuzumab purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 22;38(1):214. [Abstract]
IHC staining of GPAA1, p-AKT and Ki-67 in each group treated with vehicle or Trastuzumab (25 mg/kg, twice daily, 35 days).
-
Med
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. [Abstract]2023 Jul 14;4(7):457-477.e8. PMID: 37172578 -
J Control Release
Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity. [Abstract]2025 Apr 15:113738. PMID: 40246243 -
Biosens Bioelectron
2026 Mar 1:295:118311. PMID: 41406665 -
Cancer Lett
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. [Abstract]2020 Apr 10;475:53-64. PMID: 32006616
Trastuzumab purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Apr 10;475:53-64. [Abstract]
Cell viability was measured for cells as in shControl or shEphB4 for 9 days by crystal violet assays.
Trastuzumab purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Apr 10;475:53-64. [Abstract]
Western blot analysis of proteins as indicated in shControl or shEphB4 expressing HCC1954 cells treated with or without Transtuzumab (30 mg/mL) for 72 hours.
-
Cell Death Dis
Both direct and indirect suppression of MCL1 synergizes with BCLXL inhibition in preclinical models of gastric cancer. [Abstract]2025 Mar 12;16(1):170. PMID: 40075071
Trastuzumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Mar 12;16(1):170. [Abstract]
Trastuzumab (100 ng/mL; 24-94 h) significantly downregulated MCL1 protein levels in HER2-amplified NCI-N87 (Fig. A) and SNU-216 (Fig. B) cells, but shows no such effect in HER2-nonamplified GCIY cells (Fig. C).
-
Cell Commun Signal
Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis. [Abstract]2025 Jul 10;23(1):333. PMID: 40640807 -
Cell Commun Signal
NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer. [Abstract]2025 Feb 22;23(1):106. PMID: 39987140 -
EMBO Mol Med
2025 Feb;17(2):336-364. PMID: 39748059 -
Biomed Pharmacother
Advanced breast cancer immunotherapy: Surface modification of NK cells for embedding antibody-drug conjugates. [Abstract]2025 Jun 16:189:118245. PMID: 40527034 -
Biomed Pharmacother
An internalizing antibody targeting of cell surface GRP94 effectively suppresses tumor angiogenesis of colorectal cancer. [Abstract]2022 Jun:150:113051. PMID: 35658213 -
Elife
2019 Jun 7:8:e46983. PMID: 31172946 -
Anal Chim Acta
Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]2021 Apr 15:1154:338306. PMID: 33736796 -
Mol Cancer Ther
A DXd/TLR7-agonist dual-conjugate anti-HER2 ADC exerts robust anti-tumor activity through tumor cell killing and immune activation. [Abstract]2024 Nov 4;23(11):1639-1651. PMID: 39082754 -
Commun Biol
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors. [Abstract]2024 Dec 31;7(1):1719. PMID: 39741170 -
Int Immunopharmacol
Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3. [Abstract]2025 Sep 23:162:115160. PMID: 40614603 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Cell Rep Methods
Efficiency landscape of bioorthogonal click reactions producing bispecific antibody conjugates. [Abstract]2026 Jun 15;6(6):101416. PMID: 42019503 -
Mol Pharm
Radionuclide-Aided Improvement of the Therapeutic Efficacy of Novel Antibody-Drug Conjugates against HER2-Expressing Cancers. [Abstract]2025 Jul 7;22(7):3793-3802. PMID: 40448644 -
Nanomaterials
Label-Free, Rapid and Facile Gold-Nanoparticles-Based Assay as a Potential Spectroscopic Tool for Trastuzumab Quantification. [Abstract]2021 Nov 24;11(12):3181. PMID: 34947531 -
Transl Oncol
Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer. [Abstract]2024 Jun:44:101928. PMID: 38489873 -
Bioconjug Chem
Ion Mobility-Mass Spectrometry and Collision Induced Unfolding Reveal Linker-Payload Effects on Antibody-Drug Conjugate Higher-Order Structure and Stability. [Abstract]2026 May 20;37(5):942-949. PMID: 42063277 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Biomedicines
Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models. [Abstract]2023 Jul 25;11(8):2090. PMID: 37626587 -
EJNMMI Radiopharm Chem
2025 Apr 4;10(1):16. PMID: 40183827 -
Diagnostics (Basel)
KCTD15 Is Overexpressed in her2+ Positive Breast Cancer Patients and Its Silencing Attenuates Proliferation in SKBR3 CELL LINE. [Abstract]2022 Feb 25;12(3):591. PMID: 35328144 -
Mol Carcinog
Targeting TROP2 and Exploiting AUNIP as a Determinant of ADC Cytotoxicity and Chemosensitivity in HNSCC and ESCA Cancers. [Abstract]2026 May 7. PMID: 42096614 -
Breast Cancer Res Treat
Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing. [Abstract]2021 Jun;187(3):613-624. PMID: 33905021 -
Antibodies
Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody. [Abstract]2025 Apr 11;14(2):36. PMID: 40265417 -
PLoS One
Anti-cancer effect of a novel photodynamic therapy using glucose-linked chlorin e6 conjugated trastuzumab for HER2-positive gastrointestinal cancers. [Abstract]2026 Apr 3;21(4):e0346567. PMID: 41931583 -
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887 -
Biochem Biophys Res Commun
Swimming training attenuates doxorubicin induced cardiomyopathy by targeting the mir-17-3p/KEAP1/NRF2 axis. [Abstract]2024 Aug 19:739:150568. PMID: 39178797 -
Biochem Bioph Res Co
POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway. [Abstract]2020 Dec 10;533(3):533-539. PMID: 32988584 -
Drug Chem Toxicol
Targeting the SP1/ACSL4 axis attenuates ferroptosis in trastuzumab-induced cardiotoxicity. [Abstract]2026 Jan 29:1-10. PMID: 41607232 -
-
-
-
-
-
-
-
bioRxiv
Anthracyclines induce global changes in cardiomyocyte chromatin accessibility that overlap with cardiovascular disease loci. [Abstract]2025 Jun 16:2025.06.11.658997. PMID: 40667102 -
-
University of Michigan
-
-
-
bioRxiv
EGFR activation in cholangiocytes promotes extrahepatic bile duct regeneration after injury. [Abstract]2025 Apr 26:2025.04.22.649788. PMID: 40568138 -
-
bioRxiv
Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in Escherichia coli. [Abstract]2024 Nov 10:2024.08.12.607630. PMID: 39574765 -
-
-
-
-
-
Protocol
The effects of Trastuzumab and Trastuzumab-F(ab′)2 on the growth of JIMT-1, SKBR-3, and BT-474 cells are evaluated using the AlamarBlue method. Exponentially growing cells are harvested and plated in single wells of a 96-well flat-bottomed tissue culture plate at defined densities, ranging from 4,500-8,000 cells per well depending on the cell line. After overnight culture, the regular medium is exchanged to medium containing 0, 1, 10, or 100 μg/mL Trastuzumab or Trastuzumab-F(ab′) 2. Cell viability is tested after 72 h of treatment. Fluorescence is detected at an excitation of 544 nm, and emission is detected at 590 nm[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Trastuzumab and Trastuzumab-F(ab′)2 are given at a dose of 5 and 25 μg/g, respectively, by weekly i.p. injection. The five times greater amount of administered F(ab′)2 is chosen based on the different half-lives of IgG and F(ab′) F(ab′)2. Control mice are treated with weekly i.p. injection of 100 μL physiologic saline (saline). Animals are euthanized by CO2 inhalation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. [Content Brief]
[2]. Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. [Content Brief]
[3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trastuzumab Related Classifications
HY-P9907 Related Classifications
Powered by Bioz